Skip to main content


A needle-free drug delivery patch that helps patients receive treatments and therapies pain-free.

IF WE develop a needle-free drug delivery device, can we improve quality of life and outcomes for patients?

Medicsen was founded to identify an alternative solution for delivering medicine through needles to patients with chronic conditions. The company created a wearable patch that uses ultrasounds to deliver insulin and other drugs, eliminating the need for needles, increasing quality of life while adhering to and improving treatment results. They currently have a granted patent and  working prototype with positive results from in vivo pig trials. 


A needle-free drug delivery patch that helps patients receive treatments and therapies pain-free.


Many people fear injections and the associated pain, making medical treatments difficult to follow. This is why we created Medicsen: to provide a non-invasive, painless alternative for drug delivery, improving treatment adherence and simplifying healthcare for everyone.


Medicsen’s Smartpatch is the first truly non-invasive drug delivery system, completely free of needles. It ́s based on a patented ultrasonic system that transforms electric currents into sound vibrations to open skin pores temporarily and deliver macromolecular drugs through them. The device has a durable component that can last for up to 3 years and a disposable component to be used for up to 3 days. The absorption rate can be adjusted based on need, and is digitally and manually programmable.


For patients, the Smartpatch offers a needle-free, non-invasive and painless solution for drug delivery. A wearable, it’s discrete, easy to use, and can be programmed digitally. It also ensures better adherence to treatment plans, since those receiving medicine through it won’t be deterred by pain or other difficulties. Because it makes taking prescribed drugs easier and simpler, it contributes to overall improved treatment outcomes, which can reduce costs for hospitals and healthcare systems, too.

Their goal is to eliminate the need for the more than 30 million injections that patients must receive by 2028, increasing adherence to treatments  and saving 10% of the cost associated with needle-delivery  complications. These data points are all key priorities made by the WHO, governmental organizations like the European Union, and states like the United States.


By using the 3DEXPERIENCE platform, Medicsen is able to de-escalate risk and accelerate their time to market. They use SIMULA to run pre-analysis on the behavior of their device’s ultrasonic components and micro-fluidic systems for drug delivery. They then scaling these findings to the 3D design phase with SOLIDWORKS, moving through clinical trials with the support of MEDIDATA and exemplifying real-life examples with 3DEXCITE.

  • Eduardo  W. Jorgensen
    Eduardo W. Jorgensen
    CEO & Co-Founder
  • Patricia  Cremades
    Patricia Cremades
    CSO & Co-Founder
  • César de Mercado
    César de Mercado
    COO & Co-Founder
  • José Carlos Montesinos
    José Carlos Montesinos
    CTO & Co-Founder

Submit your project

Do you think your project is the next big thing?
Join the team !

Submit your project